Literature DB >> 12207632

Relationships between body composition parameters and fluorouracil pharmacokinetics.

Milena Gusella1, Sivia Toso, Eros Ferrazzi, Mariano Ferrari, Roberto Padrini.   

Abstract

AIMS: To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (V(ss)) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW).
METHODS: Thirty-four patients (13 females and 21 males) affected by colorectal cancer and receiving FU as adjuvant therapy entered the study. CL and Vss were determined after a 2 min i.v. injection of FU (425 mg m(-2)) and leucovorin (20 mg m(-2)). Body composition, in terms of BCM, TBW and FFM, was evaluated non-invasively by bioelectrical impedance analysis (BIA).
RESULTS: Significant but poor correlations were found between CL or V(ss) and most anthropometric parameters, including BIA-derived measures (r2 range=0.10-0.21). However, when multiple regression analysis was performed with sex, TBW and FFM as independent variables, the correlations improved greatly. The best correlation was obtained between CL and sex (r2=0.44) and between V(ss) and sex (r2=0.36). FFM-normalized CL was significantly higher in women than in men (0.030+/-0.008 vs 0.022+/-0.005 l min(-1) kg)(-1); 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females. Surprisingly, V(ss) was highly correlated with CL (r2=0.67; CL=0.52+V(ss) x 0.040). This finding may either be explained by extensive drug metabolism in extra-hepatic organs or by variable inactivation on first-pass through the lung. Both these hypotheses need experimental validation.
CONCLUSIONS: The pharmacokinetics of FU are better predicted by FFM and TBW than by standard anthropometric parameters and predictions are sex-dependent. The use of BIA may lead to improved dosing with FU.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207632      PMCID: PMC1874401          DOI: 10.1046/j.1365-2125.2002.01598.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance.

Authors:  M Gibaldi; J R Koup
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 3.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 4.  Where do we stand with 5-fluorouracil?

Authors:  H J Schmoll; T Büchele; A Grothey; W Dempke
Journal:  Semin Oncol       Date:  1999-12       Impact factor: 4.929

5.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.

Authors:  G B Haycock; G J Schwartz; D H Wisotsky
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

6.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

Authors:  G D Heggie; J P Sommadossi; D S Cross; W J Huster; R B Diasio
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

8.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

9.  Effect of uracil on metabolism of 5-fluorouracil in vitro.

Authors:  K Ikenaka; T Shirasaka; S Kitano; S Fujii
Journal:  Gan       Date:  1979-06

10.  Enzymes of uracil catabolism in normal and neoplastic human tissues.

Authors:  F N Naguib; M H el Kouni; S Cha
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

View more
  28 in total

Review 1.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

3.  Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

Authors:  C Narjoz; A Cessot; A Thomas-Schoemann; J L Golmard; O Huillard; P Boudou-Rouquette; A Behouche; F Taieb; J P Durand; A Dauphin; R Coriat; M Vidal; M Tod; J Alexandre; M A Loriot; F Goldwasser; B Blanchet
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

4.  Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer.

Authors:  Michio Kimura; Makiko Go; Mina Iwai; Eiseki Usami; Hitomi Teramachi; Tomoaki Yoshimura
Journal:  Mol Clin Oncol       Date:  2017-07-21

Review 5.  Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.

Authors:  S Gérard; D Bréchemier; A Lefort; S Lozano; G Abellan Van Kan; T Filleron; L Mourey; C Bernard-Marty; M E Rougé-Bugat; V Soler; B Vellas; M Cesari; Y Rolland; L Balardy
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

6.  Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer.

Authors:  Mami Muramatsu; Aya Tsuchiya; Seiko Ohta; Yukie Iijima; Miyuki Maruyama; Yoshiko Onodera; Megumi Hagihara; Naoki Nakaya; Itaru Sato; Kenji Omura; Soichiro Ueno; Hideo Nakajima
Journal:  Oncol Lett       Date:  2015-10-16       Impact factor: 2.967

7.  Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.

Authors:  James P Carroll; Melinda M Protani; Linda Nguyen; Matthew E Cheng; Mike Fay; Mohamed Saleem; Praga S Pillay; Euan Walpole; Jennifer H Martin
Journal:  Med Oncol       Date:  2014-02-19       Impact factor: 3.064

8.  Making the most of the imaging we have: using head MRI to estimate body composition.

Authors:  C M Lack; G J Lesser; U N Umesi; J Bowns; M Y Chen; D Case; R C Hightower; A J Johnson
Journal:  Clin Radiol       Date:  2016-01-12       Impact factor: 2.350

9.  Low skeletal muscle is associated with toxicity in patients included in phase I trials.

Authors:  Sophie Cousin; A Hollebecque; S Koscielny; O Mir; A Varga; V E Baracos; J C Soria; S Antoun
Journal:  Invest New Drugs       Date:  2013-12-17       Impact factor: 3.850

10.  Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.

Authors:  Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.